5 Best Stem Cell Therapy Stocks to Buy

2. AbbVie Inc. (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) is one of the best stem cell therapy stocks to buy. On April 23, Piper Sandler cut the price target on AbbVie Inc. (NYSE:ABBV) to $294 from $299 while reaffirming an Overweight rating on the shares. The rating update came ahead of the quarterly results, with the firm saying that the company has become a bit controversial. Despite that, Piper is making a case for why there is no need for investors to worry, as the primary worry on AbbVie Inc. (NYSE:ABBV), as seen by the firm, is driven in part by the rollout of oral IL-23-directed treatment Icotyde by Johnson & Johnson in the psoriasis setting, along with how it could impact the trajectory of Skyrizi.

The firm would anticipate that Icotyde will likely expand the overall footprint of the IL-23 category, adding that Skyrizi penetration in inflammatory bowel disease is still quite low. It also stated that although the consensus estimates on Skyrizi may have caught up with its growth trajectory, there are other parts of the business where that is not the case.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.